Epidermal growth factor receptor (EGFR) and albumin-based systems have emerged as key platforms for targeted and efficient drug delivery in breast cancer therapy, particularly for TNBC, which lacks classical hormonal and HER2 targets. This evidence concerns the gene EGFR and breast carcinoma.